

Original Article

Clinicopathological Characteristics and Survival Outcomes of Signet-Ring Cell Carcinoma: A Retrospective Study

Narges Rabeie M.D, Maryam Vajihinejad M.D, Saadat Eslami* M.D

Department of Pathology, Shahid Sadoughi Hospital, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

A B S T R A C T

Article history

Received: 20 May 2025

Accepted: 17 Aug 2025

Available online: 23 Sep 2025

Keywords

Carcinoma

Oncology

Signet ring cell

Survival Analysis

Introduction: Signet-ring cell carcinoma (SRCC) is a highly aggressive subtype of adenocarcinoma distinguished by the presence of mucin-secreting signet-ring cells. Although SRCC is rare, it is often diagnosed at advanced stages and has a poor prognosis. Knowing the clinical symptoms of SRCC can help with early diagnosis and better management of the patients. This article aims to determine the characteristics, anatomical sites involved, clinical symptoms, and survival times of patients with SRCC.

Materials and Methods: We retrospectively studied clinical records of patients diagnosed with SRCC from 2011 to 2021 in the Pathology Department of Shahid Sadoughi Hospital. We obtained the survival duration by contacting the patients. Age, sex, anatomical position of the carcinoma, and clinical symptoms of patients were identified.

Results: 143 eligible SRCC patients were enrolled, including 77 men and 66 women. The mean age of the population was 55.15 ± 16.29 years. Regarding the anatomical position of carcinoma, the highest percentage of involvement was in the stomach (67.8%), followed by the esophagus (9.1%) and lung (7.7%). The most frequent clinical symptom was abdominal pain (36.3%), followed by dyspepsia (16.8%) and Gastrointestinal obstruction (14%). Among the 57 patients for whom survival data were available, the median survival duration was 7 months. The survival rates after 1, 3, and 5 years were 40%, 32% and 24%, respectively.

Conclusion: The clinicopathological characteristics and survival time of SRCC patients were determined and reported. The stomach was the most frequently involved organ, and abdominal pain was the most reported clinical symptom.



CC BY-NC 4.0

* **Corresponding Author:** Department of Pathology, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran. **Email:** saadateslami67@gmail.com, **Tel:** +989132578583

Introduction

Signet-ring cell carcinoma (SRCC) is a highly malignant subtype of adenocarcinoma characterized by the presence of signet-ring cells. Signet-ring cells are mucin-secreting tumor cells that have a unique morphology due to the accumulation of mucin. Since SRCC has a high potential for metastasis, especially in the peritoneal region, it is considered highly aggressive and often has a poor prognosis [1]. The epidemiology of SRCC indicates that it is relatively rare in the colorectal region, occurring in only 0.1% to 2.4% of all colorectal cancers [2]. However, when SRCC is diagnosed, it often presents at advanced stages. Therefore, a significant proportion of patients exhibit metastatic disease upon diagnosis [3].

SRCC mostly originates from the stomach or colon, but other organs such as the pancreas and ovary can also be the source of carcinoma [4]. SRCC from gastric or colorectal origins can metastasize to various organs, including the liver, peritoneum, and bones [5]. However, there are some reports of SRCC metastasizing to the breast, ovaries, and lungs, highlighting its potential for hematogenous spread [6, 7].

Additionally, studies have shown that the cumulative five-year survival rate for gastric SRCC is significantly lower compared to non-signet-ring cell carcinoma (NSRCC) of the stomach [1, 8]. Specifically, patients with gastric SRCC often experience a median survival time of less than one year after diagnosis, especially when diagnosed at an advanced stage [8]. Colorectal SRCC also

exhibits poor survival rates. Research indicates that patients with colorectal cancers containing a signet-ring cell component have worse outcomes than those without this histological feature [3]. A retrospective study highlighted that even a minor signet-ring cell component in colorectal cancer is associated with significantly poorer survival rates [9].

In this study, we aimed to determine the clinical and pathological characteristics and anatomical sites involved in patients with SRCC and the survival time after the diagnosis of SRCC in a population of patients in Shahid Sadoughi Hospital. Recognizing the clinical symptoms and characteristics of SRCC can help physicians achieve early diagnosis, allowing for better intervention and patient outcomes.

Materials and Methods

Study design and included patients

The study employed a descriptive cross-sectional design on patients diagnosed with SRCC who were referred to the University Hospital of Shahid Sadoughi, Yazd, Iran, from January 2011 to December 2021. Patients above 18 years of age with a confirmed diagnosis of SRCC by an expert pathologist were enrolled. Patients with serious comorbidities, such as advanced heart disease, severe pulmonary conditions, or other chronic illnesses that could lead to death, were excluded from the study. Additionally, individuals who had been admitted to the intensive care unit and those with

immunocompromised status were not included. Medical records with significant missing data were also excluded to ensure the integrity of the results.

Procedures

Two independent investigators reviewed the patients' medical records and extracted their demographic data, anatomical position of the carcinoma, and their clinical symptoms. Then a third investigator, our validated pathologist, finalized the extracted data and reached consensus with the two primary investigators. One preassigned staff member called the patients or their relatives using the phone number in their medical record and asked them about the duration of survival after the primary diagnosis at the hospital.

Statistical analysis

All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) version 24.0 for Windows (SPSS, Chicago, IL, USA). Descriptive statistics were used to evaluate the frequency distribution of patients' characteristics according to the anatomical position of the carcinoma. The Kaplan-Meier method was used to calculate survival probabilities, and the survival curves were compared using the log-rank test.

Results

Clinicopathological characteristics

143 patients (53.84% men and 46.15% women) were included in this study. Clinical characteristics of the study population are presented in Table 1. The mean age of all

patients was 55.15 ± 16.29 , ranging from 20 to 92 years. The highest proportion of cases across all anatomical sites was observed in the 41–60 and >60 age groups, except for those involving the rectum. The most frequent site of SRCC in the study population was the stomach, accounting for 76.92% of the cases. Esophagus (9.1%), lung (7.7%), colon (7%), rectum (3.4%), breast (3.4%), and intestine (1.4%) were other sites involved with SRCC. Abdominal pain was the most commonly reported symptom, affecting 36.3% of the patients. Dyspepsia and gastrointestinal (GI) obstruction were the next two most frequent, reported by 16.8% and 14% of the patients, respectively, while vomiting was the least observed clinical symptom, present in only 1.39% of cases.

Survival analysis

The survival data were not available for 86 participants. The survival duration following primary diagnosis was recorded for 57 patients. The overall median survival time was 7 months after the initial diagnosis of SRCC. The median survival time was 12 and 6 months for subgroups of men and women, respectively. There was a notable difference between men and women; however, this difference did not reach statistical significance ($p = 0.07$). Analysis revealed that the survival rates were 40% at 1 year, 32% at 3 years, and 24% at 5 years. The survival curves of the SRCC-diagnosed patients are presented in Figure 1.

Table 1. Clinical characteristics of the study population based on the anatomical position of Signet-ring cell carcinoma

Variable	Anatomical position							
	Esophagus	Stomach	Small intestine	Colon	Rectum	Lung	Breast	Total
N	13	97	2	10	5	11	5	143
Age								
≤40	1 (3.6)	20 (71.4)	0 (0)	2 (7.1)	3 (10.7)	2 (7.1)	0 (0)	28
41-60	3 (5.4)	40 (71.4)	1 (1.8)	5 (8.9)	1 (1.8)	3 (5.4)	3 (5.4)	56
>60	9 (15.3)	37 (62.7)	1 (1.7)	3 (5.1)	1 (1.7)	6 (10.2)	2 (3.4)	59
Sex								
Male	7 (9.1)	54 (70.1)	0 (0)	5 (6.5)	3 (3.9)	8 (10.4)	0 (0)	77
Female	6 (9.1)	43 (65.2)	2 (3)	5 (7.6)	2 (3.0)	3 (4.5)	5 (7.5)	66
Clinical symptom								
Dysphagia	12 (100)	-	-	-	-	-	-	12
Gastrointestinal bleeding	-	7 (41.2)	-	5 (29.4)	5 (29.4)	-	-	17
Gastrointestinal obstruction	-	20 (100)	-	-	-	-	-	20
Vomiting	-	2 (100)	-	-	-	-	-	2
Abdominal pain	-	45 (86.5)	2 (3.8)	5 (9.6)	-	-	-	52
Dyspepsia	1 (4.2)	23 (95.8)	-	-	-	-	-	24
Dyspnea	-	-	-	-	-	8 (100)	-	8
Cough	-	-	-	-	-	3 (100)	-	3
Mass palpation	-	-	-	-	-	-	5 (100)	5

Data are presented as a number (%)




Fig. 1. Kaplan-Meier Survival Analysis of Signet Ring Cell Carcinoma patients. a) Overall survival probability for the total study population. b) Comparative survival analysis between male and female patients.

Discussion

Our study included 143 patients diagnosed with SRCC, with a mean age of 55.15 years and 53.84% being male. Similar age and sex distributions have been reported in previous studies. For example, Kown et al. described the clinicopathological features of 51 patients with gastric SRCC, reporting a mean age of 55.5 ± 11.5 years and a male proportion of 51% [10]. Given the relative rarity of SRCC, conducting studies with large sample sizes remains a significant challenge.

Our findings revealed that most patients were over 60 years of age; however, a significant portion of colorectal SRCC cases occurred in individuals younger than 40. This finding contrasts with earlier studies, which typically reported a mean or median age between 50 and 70 years for colorectal SRCC patients [11]. Despite this, recent literature suggests a shifting trend. Several studies have shown that SRCC, particularly in the stomach and colon, tends to present at a younger age compared to NSRCCs in the same anatomical regions [12, 13]. Moreover, a study by Tawadros et al. reported a 3.6% annual increase since 2010 in the incidence of colorectal SRCC among patients under 40 years of age [14], which may partially explain the younger age distribution observed in our study. Although this trend is not universally supported, it highlights a possible evolving epidemiological pattern that needs further investigation.

In our study, the stomach was identified as the most commonly affected site, accounting for 76.92% of cases, followed by the esophagus,

lung, colon, rectum, breast, and small intestine. Similarly, Wu et al. analyzed a large cohort of over 24,000 patients and reported that the stomach was the primary site of SRCC in 63.4% of cases [15]. Their study also documented a higher proportion of colorectal SRCC cases compared to ours and identified less common sites such as the pancreas, bladder, and gallbladder. These discrepancies are likely attributable to the significantly larger sample size in their study, which allowed for the identification of a broader range of anatomical sites affected by SRCC. Despite these insights, the origin and underlying molecular mechanisms driving SRCC development remain poorly understood. However, consistent with previous literature, our findings reinforce that gastrointestinal organs, particularly the stomach, are the most frequently involved sites, and that metastases often arise from these primary locations [1, 4, 15]. Further research into the molecular pathways involved in SRCC is essential to better understand its origin and pathogenesis.

In our study, the most commonly observed clinical symptoms of SRCC were abdominal pain, dyspepsia, and gastrointestinal (GI) obstruction. Gastric SRCC typically presented with abdominal pain, dyspepsia, and GI obstruction, while SRCC involving the colon, intestine, and esophagus was often associated with abdominal pain or GI bleeding. These findings are consistent with previous studies, which have shown that gastric SRCC often presents with abdominal pain, dysphagia, early

satiety, and weight loss [16, 17]. Tumors located in the rectum may cause rectal bleeding, changes in bowel habits, and tenesmus, while SRCC lesions in the colon are associated with abdominal discomfort, weight loss, and anemia [18, 19]. Since the clinical symptoms of SRCC are closely tied to tumor location and progression stage, many patients exhibit minimal or no symptoms in the early phases, delaying diagnosis until the disease has advanced [4]. These findings highlight the critical importance of early detection and diagnosis in improving outcomes for SRCC patients.

The survival rates of patients after 1, 3, and 5 years were 40%, 32%, and 24%, respectively. The median length of survival was 7, 12, and 6 months for the total population, men, and women, respectively. The subgroup of men had a longer survival time compared to women; however, statistical significance was not reached. One previous study reported the median survival rate of SRCC patients was 12 months, and 1-, 3-, and 5-year survival rates were 49.5%, 28.9% and 24%, respectively [15]. Recent evidence indicates that SRCC of the stomach and colon has a worse prognosis and less survival time compared to NSRCC [20, 21]. Overall, the prognosis for SRCC across its various types remains challenging, characterized by high mortality rates and limited survival time, particularly in advanced cases. Effective management strategies focused on early detection and tailored chemotherapy have been shown to slightly improve survival rates [22].

Although we reviewed the patients' records over 10 years, we encountered several limitations in this study. First, our sample size was constrained due to the rarity of SRCC, and studies on bigger populations can be performed. Second, in the case of survival analysis, we couldn't access a significant number of patients due to missing or incorrect phone numbers. Third, this study lacks a comparative analysis of SRCC with other types of carcinomas, and future studies can be carried out using this method.

Conclusion

This retrospective study provides a descriptive overview of the clinicopathological characteristics, anatomical distribution, clinical presentation, and survival outcomes of patients diagnosed with SRCC over ten years. Our findings confirm that the stomach is the most commonly affected organ, and abdominal pain is the predominant symptom. The disease predominantly affects individuals over the age of 60, with a slight male predominance. The overall prognosis for SRCC remains poor, with a median survival time of 7 months and a 5-year survival rate of only 24%. These results highlight the aggressive nature of SRCC and underscore the need for improved strategies in early detection and treatment. Future studies with larger cohorts and comparative analyses are necessary to further understand the behavior of SRCC and to optimize patient management.

Ethical Considerations

The study was performed according to the Declaration of Helsinki, and the study design was

approved by Shahid Sadoughi University's ethics committee (IR.SSU.MEDICINE.REC.1401.161). We obtained informed consent from each patient or their relatives to use their data for educational or research purposes. No personal data was used at the time of data extraction.

Funding

This study was conducted without any external funding or financial support.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgments

We would like to express our deepest gratitude to our colleagues at Shahid Sadoughi Hospital, especially the Department of Pathology, for their invaluable support. We are also profoundly thankful to all participants for agreeing to take part in this study. Additionally, we acknowledge the use of a large language model (ChatGPT, developed by

OpenAI, GPT-4, 2025) for assistance with grammar correction during manuscript preparation; the tool was not used for data analysis, interpretation, or the generation of original scientific content.

Data Availability

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

Authors' Contributions

N.R. was responsible for assembling data, conducting the literature review, providing feedback on the manuscripts. M.V. was responsible for writing the manuscript and improving the interpretation of the results. S.E. was responsible for designing the review protocol, writing the manuscript, assembling data, analyzing data, and interpreting analyses.

References

- [1]. Mizushima T, Nomura M, Fujii M, Akamatsu H, Mizuno H, Tominaga H, et al. Primary colorectal signet-ring cell carcinoma: Clinicopathological features and postoperative survival. *Surgery Today* 2010; 40(3): 234-38.
- [2]. Tanaka Y, Chino O, Kajiwarra H, Hanashi T, Nakamura T, Makuuchi H. A rare case of esophageal metastasis from signet-ring cell carcinoma of the cecum. *Surgical Case Reports* 2023; 9(1): 186.
- [3]. Bhawani S, Mubashira H. Increasing incidence of colorectal carcinoma in younger age group in our population. *J Muhammad Med Coll.* 2016; 6(2): 34-7.
- [4]. Shoji T, Takeshita R, Saito T, Aida T, Sasou S, Baba T. A case of primary ovarian signet-ring cell carcinoma treated with S-1/CDDP therapy. *Journal of Ovarian Research* 2020; 13(1): 33.
- [5]. Iwai N, Okuda T, Harada T, Oka K, Hara T, Inada Y, et al. Gastric metastasis from colorectal cancer mimicking a submucosal tumor. *Case Reports in Gastroenterology* 2020; 14(2): 338-45.
- [6]. Buerba-Vieregge HH, Fernández-Ferreira R, Soberanis-Piña PD, Ildefonso Roberto De la P-L, Navarro-García LM, Macari-Jorge A. Breast metastasis of gastric signet ring cell carcinoma: A case report and literature review. *Case Reports in Oncology* 2021; 14(1): 165-72.
- [7]. Castro CY, Moran CA, Flieder DG, Suster S. Primary signet ring cell adenocarcinomas of the lung: A clinicopathological study of 15 cases. *Histopathology* 2001; 39(4): 397-401.
- [8]. Jiang C, Wang Z, Sun Z, Liu F, Yu M, Xu H. Clinicopathologic characteristics and prognosis of signet ring cell carcinoma of the stomach: Results from a Chinese mono-institutional study. *Journal of Surgical Oncology* 2011; 103(7): 700-703.
- [9]. Tan Y, Fu J, Li X, Jiao Y, Jiang M, Ding K, et al. A minor signet-ring cell component associated with poor prognosis in colorectal cancer patients: A 26-year retrospective study in China. *Plos One* 2015; 10(3): 121944.
- [10]. Kwon KJ, Shim KN, Song EM, Choi JY, Kim SE, Jung HK, et al. Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach. *Gastric Cancer* 2014; 17(1): 43-53.
- [11]. An Y, Zhou J, Lin G, Wu H, Cong L, Li Y, et al. Clinicopathological and molecular characteristics of colorectal signet ring cell carcinoma: a review. *Pathology and Oncology Research* 2021; 27: 1609859.
- [12]. Kumar M, Tata MD, Lah NA. A case of rectal cancers in teenager: A conundrum of genetics and clinical medicine. *Annals of Medicine and Surgery* 2021; 65: 102353.
- [13]. Weng MT, Chao KH, Tung CC, Chang HC, Shih IL, Lin BR, et al. Characteristics of primary signet ring cell carcinoma of colon and rectum: A case control study. *BMC Gastroenterol.* 2022; 22(1): 173.

- [14]. Tawadros PS, Paquette IM, Hanly AM, Mellgren AF, Rothenberger DA, Madoff RD. Adenocarcinoma of the rectum in patients under age 40 is increasing: Impact of signet-ring cell histology. *Diseases of the Colon & Rectum* 2015; 58(5): 474-78.
- [15]. Wu SG, Chen XT, Zhang WW, Sun JY, Li FY, He ZY, et al. Survival in signet ring cell carcinoma varies based on primary tumor location: A surveillance, epidemiology, and end results database analysis. *Expert Review of Gastroenterology & Hepatology* 2018; 12(2): 209-14.
- [16]. Lu M, Yang ZY, Feng Q, Mei Y, Zhang Y, Mao C, et al. The characteristics and prognostic value of signet ring cell histology in gastric cancer. *Medicine* 2016; 95(27): 4052.
- [17]. Hass HG, Smith U, Jäger C, Schäffer M, Wellhäußer U, Hehr T, et al. Signet ring cell carcinoma of the stomach is significantly associated with poor prognosis and diffuse gastric cancer (Lauren's): Single-center experience of 160 cases. *Onkologie* 2011; 34(12): 682-86.
- [18]. Shi T, Huang M, Han D, Tang X, Chen Y, Li Z, et al. Chemotherapy is associated with increased survival from colorectal signet ring cell carcinoma with distant metastasis: A Surveillance, epidemiology, and end results database analysis. *Cancer Medicine* 2019; 8(4): 1930-940.
- [19]. Hugen N, Verhoeven RHA, Lemmens VEPP, Aart CJV, Elferink MAG, Radema SA, et al. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor. *International Journal of Cancer* 2014; 136(2): 333-39.
- [20]. Zhao S, Lv L, Zheng K, Tian Y, Zheng JC, Jiang CG. Prognosis and biological behavior of gastric signet-ring cell carcinoma better or worse: A meta-analysis. *Frontiers in Oncology* 2021; 11: 603070.
- [21]. Fadel MG, Malietzis G, Constantinides V, Pellino G, Tekkis P, Kontovounisios C. Clinicopathological factors and survival outcomes of signet-ring cell and mucinous carcinoma versus adenocarcinoma of the colon and rectum: A systematic review and meta-analysis. *Discover Oncology* 2021; 12(1): 5-12.
- [22]. Yang L, Wang M, He P. Clinicopathological characteristics and survival in colorectal signet ring cell carcinoma: A population-based study. *Scientific Reports* 2020; 10(1): 10460.